An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells). It is available as a tablet. The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug Enoxaparin. Enoxaparin, a so-called low molecular heparin, is approved and widely used in the area of thromboprophylaxis and will be given once daily subcutaneously. In this study 4 different doses of the investigational drug BAY59-7939 will be tested in comparison to Enoxaparin. You will receive during the study either one of the following BAY59-7939 treatments or Enoxaparin. The following doses of BAY59-7939 will be tested: Dose I ; Dose II, Dose III, Dose IV. This study will run for approximately 7 months in a number of countries. In total, up to 600 patients may participate in this study.

Study Overview

• Status: Completed
• Conditions: Venous Thromboembolism
• Intervention / Treatment: Drug: Enoxaparine; Drug: Rivaroxaban (BAY59-7939); Drug: Rivaroxaban, (BAY59-7939); Drug: Rivaroxaban, (BAY59-7939); Drug: Rivaroxaban, (BAY59-7939)

• Study Type: Interventional
• Enrollment (Actual): 613
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
    • Red Deer, Alberta, Canada, T4N 4E7
  • British Columbia
    • Kelowna, British Columbia, Canada, V1Y 1T2
    • Vancouver, British Columbia, Canada, V6Z 1Y6
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A 1M3
  • New Brunswick
    • Fredericton, New Brunswick, Canada, E3B 5N5
  • Ontario
    • Barrie, Ontario, Canada, L4M 6M2
    • Kitchener, Ontario, Canada, N2G 1G3
    • Niagara Falls, Ontario, Canada, L2G 5X8
    • Oshawa, Ontario, Canada, L1G 2B9
    • Ottawa, Ontario, Canada, K1H 8L6
    • Peterborough, Ontario, Canada, K9J 7H8
    • Richmond Hill, Ontario, Canada, L4C 4Z3
    • St. Catharines, Ontario, Canada, L2R 5K3
    • Sudbury, Ontario, Canada, P3E 6C3
    • Thunder Bay, Ontario, Canada, P7B 6V4
    • Toronto, Ontario, Canada, M3M 2G2
    • Welland, Ontario, Canada, L3B 4W6
  • Prince Edward Island
    • Charlottetown, Prince Edward Island, Canada, C1A 1L2
  • Quebec
    • Montreal, Quebec, Canada, H3G 1A4
    • Quebec City, Quebec, Canada, G1J 1Z4
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
  • Arizona
    • Phoenix, Arizona, United States, 85023
    • Tucson, Arizona, United States, 85712
  • California
    • La Mesa, California, United States, 91942-3019
    • Torrance, California, United States, 90502-2004
  • Colorado
    • Aurora, Colorado, United States, 80012
    • Aurora, Colorado, United States, 80011-6798
  • Florida
    • Jacksonville, Florida, United States, 32216
    • Palm Beach Gardens, Florida, United States, 33410
    • Sarasota, Florida, United States, 34239
    • St. Petersburg, Florida, United States, 33703
  • Georgia
    • Decatur, Georgia, United States, 30033
  • Ohio
    • Cincinnati, Ohio, United States, 45219
  • Texas
    • Dallas, Texas, United States, 75231
    • Lubbock, Texas, United States, 79410

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male subjects aged 18 years or above and postmenopausal female subjects
• Subjects scheduled for elective total knee replacement
• Subjects written informed consent for participation after receiving detailed written and oral information previous to any study specific procedures

Exclusion Criteria:

Related to medical history:

• Any prior DVT or PE
• Myocardial infarction (MI), TIA or ischaemic stroke within the last 6 months prior to randomization
• History of heparin-induced thrombocytopenia, allergy to heparins
• Intracerebral or intraocular bleeding within the last 6 months prior to randomization
• History of gastrointestinal disease (e.g. active peptic ulcer) with gastrointestinal bleeding within the last 6 months prior to randomization
• History or presence of gastrointestinal disease which could result in an impaired absorption of the study drug (e.g. severe active inflammatory bowel disease, short gut syndrome)
• Amputation of one leg

Related to current symptoms or findings:

• Heart insufficiency NYHA III-IV

• Congenital or acquired haemorrhagic diathesis (PT INR/aPTT not within normal limits)including patients with acquired or congenital thrombophilia

  • Thrombocytopenia (platelets < 100,000/µl)
  • Macroscopic haematuria
  • Allergy to contrast media
  • Severe hypertension (SBP > 200mmHg, DBP > 100 mmHg)
  • Impaired liver function (transaminases > 2 x ULN)
  • Impaired renal function (serum creatinine > 1.5 x ULN or decreased creatinine clearance < 30ml/min)
  • Active malignant disease
  • Presence of active peptic ulcer or gastrointestinal disease with increased risk of gastrointestinal bleeding
  • Body weight < 45 kg
  • Drug- or alcohol- abuse

Related to current treatment:

• Therapy with oral anticoagulants (e.g. phenprocoumon, warfarin-sodium, heparins and factor Xa inhibitors other than study medication) and fibrinolytic therapy
• Therapy with acetylic salicylic acid or other thrombocyte aggregation inhibitors (e.g. clopidogrel, dipyridamole and ticlopidine) should be stopped one week before enrollment. Patient not able to stop ASA therapy will be excluded
• All other drugs influencing coagulation, (exception: NSAIDs with half life < 17 hrs will be allowed)
• Systemic and topical treatment with azole compounds (e.g. ketoconazole, fluconazole, itraconazole). Azole compounds should be stopped at least four days before enrollment

Miscellaneous:

• Planned intermittent pneumatic compression during active treatment period
• Planned epidural anaesthesia with indwelling epidural catheter (spinal and epidural anaesthesia without indwelling catheter is allowed)
• Therapy with another investigational product within 30 days prior to the start of the study
• Concomitant participation in another trial or study

Removal of Subjects from Study:

A subject who withdraws is one who discontinued a clinical study for any reason.

Subjects may be withdrawn from the study for the following reasons:

• At their own request or at the request of their legally acceptable representative
• If, in the investigator's opinion, continuation in the study would be detrimental to the subject's well-being
• At the specific request of the sponsor

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1	Drug: Rivaroxaban (BAY59-7939); 2.5mg bid
Experimental: Arm 2	Drug: Rivaroxaban, (BAY59-7939); 5mg bid; Drug: Rivaroxaban, (BAY59-7939); 10 mg bid; Drug: Rivaroxaban, (BAY59-7939); 20mg bid
Experimental: Arm 3	Drug: Rivaroxaban, (BAY59-7939); 5mg bid; Drug: Rivaroxaban, (BAY59-7939); 10 mg bid; Drug: Rivaroxaban, (BAY59-7939); 20mg bid
Experimental: Arm 4	Drug: Rivaroxaban, (BAY59-7939); 5mg bid; Drug: Rivaroxaban, (BAY59-7939); 10 mg bid; Drug: Rivaroxaban, (BAY59-7939); 20mg bid
Experimental: Arm 5	Drug: Enoxaparine; 30mg bid
Experimental: Arm 6	Drug: Enoxaparine; 30mg bid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Composite endpoints of Deep vein Thrombosis (proximal and/or distal),non fatal PE and death from all causes	5-9 days after surgery or earlier in case of symptoms indicating deep vein Thrombosis.

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of DVTs (total, proximal, distal)	Day 6-10
Incidence of symptomatic VTEs	Day 6-10
The composite endpoint that results from the primary endpoint by substituting VTE related death for all deaths	Day 6-10
Incidence of symptomatic VTEs (total, PE, DVT)	Day 6-10

Collaborators and Investigators

• Sponsor: Bayer

Study record dates

Study Major Dates

• Study Start: February 1, 2004
• Primary Completion (Actual): November 1, 2004
• Study Completion (Actual): November 1, 2004

Study Registration Dates

• First Submitted: November 21, 2006
• First Submitted That Met QC Criteria: November 21, 2006
• First Posted (Estimate): November 22, 2006

Study Record Updates

• Last Update Posted (Estimate): December 23, 2014
• Last Update Submitted That Met QC Criteria: December 18, 2014
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: Prevention of venous thromboembolism
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Embolism and Thrombosis; Thromboembolism; Venous Thromboembolism; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Fibrinolytic Agents; Fibrin Modulating Agents; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Rivaroxaban; Enoxaparin; Enoxaparin sodium
• Other Study ID Numbers: 10945